# Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

> clinical trial · VERIFIED · 2026-07-21

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Inherited Bone Marrow Failure Syndrome

- Company: National Cancer Institute (NCI)
- Sector: Inherited Bone Marrow Failure Syndrome
- Primary source: https://clinicaltrials.gov/study/NCT06090669

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.